PartnershipJun 22, 2026, 08:23 AM
Nexentis Subsidiary MitoCareX Partners with Boltz AI for Drug Discovery
AI Summary
Nexentis Technologies Inc. announced that its wholly-owned subsidiary, MitoCareX Bio Ltd., has partnered with Boltz, PBC, an AI research lab. This collaboration aims to accelerate the identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins by combining MitoCareX’s proprietary MITOLINE® algorithm platform with Boltz’s AI foundation models. The integrated approach is expected to strengthen virtual screening campaigns for challenging transporter proteins and improve hit identification. Nexentis also maintains an investment strategy in European renewable energy assets.
Key Highlights
- MitoCareX, a wholly-owned subsidiary of Nexentis, entered an engagement with Boltz, PBC.
- The partnership combines MitoCareX’s MITOLINE® algorithm with Boltz’s AI foundation models.
- The initiative aims to accelerate identification of novel small-molecule scaffolds targeting selected solute carrier (SLC) proteins.
- MitoCareX previously identified initial hit molecules against an SLC25 target using MITOLINE®.
- Boltz, PBC has publicly highlighted deployments of its models with industry partners including Pfizer and Takeda.
- Nexentis Technologies Inc. also invests in four solar projects across three European Union countries.
Price Impact
More from NXTS